Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
autologous tumor cell vaccine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| autologous tumor cell vaccine | BIOLOGICAL | - |
| sargramostim | BIOLOGICAL | - |
| tumor-draining lymph node lymphocyte therapy | BIOLOGICAL | - |
| cyclophosphamide | DRUG | - |
| conventional surgery | PROCEDURE | - |
DISEASE CHARACTERISTICS: Histologically proven glioblastoma multiforme or anaplastic astrocytoma Prior surgical resection and radiotherapy completed approximately 1 month prior to study PATIENT CHARACTERISTICS: Age: Over 18 Performance status: ECOG 0-1 OR Karnofsky 70-100% Life expectancy: Not spec...
Autologous tumor cell vaccine is an investigational cancer therapy being studied for the treatment of brain and central nervous system tumors, specifically glioblastoma multiforme. It is a personalized approach that uses a patient's own tumor cells to create a vaccine intended to stimulate an immune response against the cancer.
Autologous tumor cell vaccine is being developed by Community Health Systems, Inc., a company publicly traded under the ticker symbol CYH. The company is conducting clinical research to evaluate the safety and effectiveness of this investigational therapy in patients with brain and central nervous system tumors.
Autologous tumor cell vaccine is currently in Phase 2 clinical development. It is an investigational agent, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its potential as a treatment for brain and central nervous system tumors.
Autologous tumor cell vaccine has been studied in one completed clinical trial, identified as NCT00003185, titled "Biological Therapy in Treating Patients With Glioblastoma Multiforme." This Phase 2 trial enrolled 40 participants in the United States and evaluated the vaccine in patients with brain and central nervous system tumors.
No, autologous tumor cell vaccine is not FDA approved. It is an investigational therapy currently in Phase 2 clinical development. The completed clinical trial, NCT00003185, has finished, but the therapy has not yet received regulatory approval for the treatment of brain and central nervous system tumors.